Omnicare Inc

Omnicare — Q2 2013 Earnings Presentation

17 slides from Omnicare's earnings presentation, Jul 24, 2013

  1. Slide 1: Omnicare

    Omnicare

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain of mace lovey it i the following re fe ‘d-lookir i i vate ities Litigation Reform Act of 1995. These forward-| Hooking statements include, but are not tte to, all statements ir ue intent, belief or Current regarding Such and involve k and orleaan risks, uncertainti

  3. Slide 3: Table of Contents

    Table of Contents second:-Quatter 2013 HIQhIIQtsS \ccusssaseswenanaweessaremmameatna aioe 4 _ Operating Metrics — Script Data | Operating Metrics — Long-Term Care Bed Data... Gross Profit & Adjusted Operating Income Adjusted Net Income & Cash EPS....... Adjusted Operating Income by Segment Cash Flow

  4. Slide 4: Second-Quarter 2013 Highlights

    Second-Quarter 2013 Highlights © Gross profit of $378.5M; gross margin expanded 19 bps to 24.11% Adjusted EBITDA of $178.6M; 4.9% year-over-year increase Adjusted cash earnings per diluted share’) of $0.90; 8.4% higher than 2Q12 of $0.83 Cash flows from operations of $153.8M; 103% of adjusted operat

  5. Slide 5: Operating Metrics: Script Data

    Operating Metrics Script Data Sequential Prior Year Increase / Increase / (In thousands, except %5) 202013 102013 (Decrease) _2Q2012 (Decrease) Long-Term Care Group Scripts: Generic scripts dispensed 20,688 20,809 (0.6%) 20,519 0.8% Branded scripts dis 4,263 4,322 (1.4%) 43 (2.6%) Over-the-counter s

  6. Slide 6: Operating Metrics: Long-Term Care Bed Data

    | Totals may not fool de to ounding dterences B Operating Metrics Long-Term Care Bed Data Sequential Increase / (In thousands) 2Q 2013 _1Q2013 (Decrease) Beds served: Begining of period - LTC Beds 969 970 (1) Net change in beds served 1 1 2 End of at LTC Beds “ 969 969 0) Patient related beds 917 91

  7. Slide 7: Gross Profit & Adjusted Operating Income

    Gross Profit & Adjusted Operating Income") —___Sequential__ Prior Year Increase / crease / In millions, except per share data and %s 202013 _1@2013 (Decrease) _2@ 2012 ibosreas Net sales $ 1,569.9 $ 1,525.0 2.9% $ 1,536.0 2.2% Cost of sales 4191.4 1,154.2 3.2% 4,168.7 1.9% Gross profit $ 3785 $ 3708

  8. Slide 8: Adjusted Net Income & Cash-based EPS

    B Adjusted Net Income & Cash- based EPS) In inion except per share data and %s ‘Adjusted operating income dusted interest expense, net of investment income Adjusted income before income taxes Income taxes Adjusted net income Intangible asset amortization - after ~ Goodwill amortization - tax deducti

  9. Slide 9: Adjusted Operating Income by Segment

    ih 2 Adjusted Operating Income by Segment “) 202013 _ 102013 In millions, except %s ene Tor Care Group $ 1,222.4 $ 1,2037 ? 165.1 162.1 Rate 13.51% 13.47% in whole numbers Per scr Net sales / script 4131 $§ 40.30 ‘Adjusted operating income /script _$ 5.58 $ 5.43 In millions, except %s Speci fatty Ca

  10. Slide 10: Cash Flows

    Cash Flows “) ie millions, except %s let income ajetments to reconcile net income to net cash flows Loss from disposition Other operating activities Changes in certain assets and labios, a of effects _ from racosision and divestiture sash flows from operating one Capital expenditures Dividends paid

  11. Slide 11: Cash Deployment

    Cash Deployment In millions, except %s Net cash flows from operating activities (reported) Capital expenditures Acquisitions Net debt and long term borrowings repayment “") Capital returned: Dividends pai % of net cash be from operating acti Capital Returned to Stockholders (in millions, except %5)

  12. Slide 12: Full-Year 2013 Guidance

    Full-Year 2013 Guidance Pe Previous Guidance “) | Current Guidance @ + Revenue $6.1B to $6.2B $6.1B to $6.3B + Adjusted cash earnings per diluted rare $3.47 to $3.57 $3.56 to $3.64 * Cash flow from operations $450M to $500M $475M to $525M 4, Guidance provided on Api24, 2013, 2 Guidance proved on Jy

  13. Slide 13: Appendix

    RNY ly, “yg; Omnicare Appendix

  14. Slide 14: Capital Structure

    Capital Structure in $ mi ions) Major Debt Maturity Schedule) (in $ millions) WAS of 9/30/10 As of 6/30/13 2010 2015 2020 2030 try ‘wer atiined as of June 30, 2013 and ae asied on the balance sheet as curent debt. 2035 201

  15. Slide 15: Working Capital Management

    Working Capital Management Five Quarter Trend() 40 1s 35 70 30 65 25 60 20 55 15 50 10 45, 5 40 0 35 2012 3012 4qi2 1013 2013 4. DOH= Ending Inventory (Quai Cost of Sales /Daysin Quarter) DSO = Ending Account Receivable (Quarterly Sles/Daysin Quai)

  16. Slide 16: Selected Branded Drug Patent Expirations

    Selected Branded Drug Patent Expirations)) 2Q 2013 3Q-4Q 2013 FY 2014 Atacand IR Aciphex Actonel Rilutek Bromday Aricept (23mg tab) Zovirax Cymbalta Avelox Lidoderm Celebrex Lunesta Detrol LA Niaspan Diovan IR Prezista Evista Temodar Exelon (patch) Trilipix Fosrenol Xeloda Invega Megace ES Nasonex N

  17. Slide 17: Omnicare

    Omnicare

Omnicare — Q2 2013 Earnings Presentation on 6ix